Global Vardenafil Hydrochloride Trihydrate Market Size, Share and Trends Analysis Report, By Disease (Erectile Dysfunction and Others), By Application (Pharmaceuticals, Health Products, and Others), By End User (Hospital, Clinic, and Others), Forecast (2022-2028)

The vardenafil hydrochloride trihydrate market is anticipated to grow at a significant CAGR 4% during the forecast period (2022-2028). Vardenafil hydrochloride trihydrate is a drug used in the treatment of erectile dysfunction. This drug is an inhibitor of cyclic guanosine monophosphate. It comes in a class of specific phosphodiesterase type 5. At the time of penile erection which is initiated by the relaxing of muscles in the corpus cavernosum, nitric oxide is released from the corpus cavernosum. This release is from nerve endings and endothelial cells. In the corpus cavernosum, nitric oxide is responsible to activate the enzyme guanylate cyclase. This process increases the synthesis of cyclic guanosine monophosphate. Cyclic guanosine monophosphate increases the flow of blood in the muscles of the penis which enhances erection. The inhibition of cyclic guanosine monophosphate specific phosphodiesterase type 5 increases the duration of erection in the human body.

The global vardenafil hydrochloride trihydrate market is segmented by disease and by end-user. Based on disease, the market is sub-segmented into erectile dysfunction and others. Based on end-user, the market is sub-segmented into hospitals, clinics, and others. Erectile dysfunction is a condition in which a male human is not able to keep an erection firm enough to do sexual intercourse. As per Health experts, this condition is normal if it happens sometimes but a cause of concern if it is a consistent process. Erectile dysfunction can lead to stress, anxiety, and lower self-confidence. As per the Massachusetts male aging study, the prevalence rate of erectile dysfunction is 52%. Erectile dysfunction affects 26% of men who are below 40 years. In the age group of 20 to 29 years, the prevalence of erectile dysfunction is 8%.

The global vardenafil hydrochloride trihydrate market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The Asia Pacific is expected to drive the market during the forecast period. A major reason for the rise in the market is the prevalence of hypertension and diabetes. People with hypertension and diabetes are likely to have erectile dysfunction.   

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Disease
  • By Application
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bayer AG, Dr.Reddy’s Laboratories Ltd., Mylan Laboratories Limited.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Vardenafil Hydrochloride Trihydrate Market Report By Segment

By Disease

• Erectile Dysfunction
• Others

By Application

• Pharmaceuticals
• Health Products
• Others

By End-User

• Hospital
• Clinic
• Others